Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2050-7771
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript ; volume:9 ; number:1 ; day:20 ; month:12 ; year:2021 ; pages:1-5 ; date:12.2021
Biomarker Research ; 9, Heft 1 (20.12.2021), 1-5, 12.2021
- Creator
-
Voruz, Sophie
Blum, Sabine
de Leval, Laurence
Schoumans, Jacqueline
Solly, Françoise
Spertini, Olivier
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40364-021-00343-3
- URN
-
urn:nbn:de:101:1-2022041420091055085715
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:37 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Voruz, Sophie
- Blum, Sabine
- de Leval, Laurence
- Schoumans, Jacqueline
- Solly, Françoise
- Spertini, Olivier
- SpringerLink (Online service)
Other Objects (12)
Bcl2 inhibitor venetoclax +/− Anti-CD20: what do deep remissions mean?
Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma
CD20 and CD19 targeted vectors induce minimal activation of resting B lymphocytes
CD19 and CD20 Targeted Vectors Induce Minimal Activation of Resting B Lymphocytes
Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
Daratumumab
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
Bcl2 inhibitor venetoclax +/− Anti-CD20: what do deep remissions mean?
Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma
CD20 and CD19 targeted vectors induce minimal activation of resting B lymphocytes
CD19 and CD20 Targeted Vectors Induce Minimal Activation of Resting B Lymphocytes
Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
Daratumumab
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
Bcl2 inhibitor venetoclax +/− Anti-CD20: what do deep remissions mean?
Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma
CD20 and CD19 targeted vectors induce minimal activation of resting B lymphocytes
CD19 and CD20 Targeted Vectors Induce Minimal Activation of Resting B Lymphocytes
Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
Daratumumab
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy